7.7% Below Target

The consensus price target for EMR is $162.29, close to the current price of $150.66 (7.7% implied move). Based on 41 analyst estimates, the stock appears fairly valued near current levels.

EMR has a consensus rating of "Buy" based on 41 Wall Street analysts. The rating breakdown is predominantly bullish, with 21 Buy/Strong Buy ratings. The consensus 12-month price target of $162.29 implies 7.7% upside from current levels.

EMR trades at a forward P/E of 23.1564x, representing a moderate valuation. With analysts targeting $162.29 (7.7% implied move), the stock appears reasonably valued with upside.

The most bullish Wall Street analyst has a price target of $185 for EMR, while the most conservative target is $125. The consensus of $162.29 represents the median expectation. Our quantitative valuation model projects a bull case target of $285 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.

EMR is heavily covered by Wall Street, with 41 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 21 have Buy ratings, 17 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.

The 12-month EMR stock forecast based on 41 Wall Street analysts shows a consensus price target of $162.29, with estimates ranging from $125 (bear case) to $185 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $217, with bear/bull scenarios of $136/$285.

Our quantitative valuation model calculates EMR's fair value at $217 (base case), with a bear case of $136 and bull case of $285. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 51/100.

EMR trades at a forward P/E ratio of 23.2x based on next-twelve-months earnings estimates compared to a trailing P/E of 37.3x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.

EMR appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $162.29 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.

EMR analyst price targets range from $125 to $185, a 37% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $162.29 consensus represents the middle ground. Our model's $136-$285 range provides an independent fundamental perspective.